Juniper Publishers-Cancer Therapy Oncology International Journal

  Cancer Therapy & Oncology International Journal Abstract Neurofibromatosis type 1 (NF1), formerly known as von Recklinghausen’s disease is a nervous system tumor disorder of variable expressivity. Malignant solitary fibrous tumors (SFT) are rare spindle cell soft tissue tumors. We report a case of a 35-year-old male who presented clinically with NF1 and a mass that mimicked a nerve sheath tumor radiologically, but pathologically was, in fact, a malignant solitary fibrous tumor. Based on a literature review, the association between NF1 and malignant SFT has never been published. Keywords: Neurofibromatosis type 1; Malignant solitary fibrous tumor Abbrevations: SFT: Solitary Fibrous Tumors; NF1: Neurofibromatosis type 1 Mini Review Neurofibromatosis type 1 (NF1) is a multisystem disease characterized by cutaneous findings, as well as benign and malignant tumors o...

  Cancer Therapy & Oncology International Journal Abstract The purpose of the work was to study the effect of different single radiation doses of X-rays on the pediatrics Rhabdomyosarcoma (RMS) cells in vitro . In addition, to construct the survival curve for the RMS cells and determine some crucial radiobiological parameters used for calculations of tumor cell kill in radiotherapy treatment of pediatrics RMS tumors. An established in vitro cell culture model employing the RMS tumor cell lines was used for this study. Cells were exposed to single doses of 0, 4, 8, 12, 16, and 20 Gy from a 6 MV X-rays photon beam energy. The clonogenic cell survival assay method was used to quantify the RMS cell survival. The survival curve was fitted by the single-hit multi-target and linear-quadratic models. The mean lethal dose (D 0 =3.2 Gy), the extrapolated number (n=11) represents a measure of the width of the survival curve shoulder and corresponds to th...

  Cancer Therapy & Oncology International Journal Abstract The place of quackery is important in the history of medicine. In this context, cancer quackery is in the forefront of it. Therefore, English literature and foreign translations are searched from 1635 to1886 in order to obtain some memorable perspectives of the psychological aspects of cancer quackery. Keywords: Quackery; Cancer; Treatment; Psychology; History Historical Perspectives Sir Macfarlane Burnet [1], who is far famed for his pioneer work on cancer surveillance, recommended clearly in his Brailsford Robertson Memorial Lecture that scientists should acquaint themselves with historical antecedents. Therefore, this paper documents such antecedents in respect of the drug treatment modalities used by cancer quacks. Quacks were presented in the 1725 History of Physic by Friend [2] concerning “how much ...

  Cancer Therapy & Oncology International Journal Abstract Tumor heterogeneity, especially intra-tumor heterogeneity, is a crucial factor underlying difficulties in cancer treatment and failure of a number of current therapeutic modalities, even of molecularly targeted therapies. The conventional follow-up care is based on regular observation of protein markers in combination with computed tomography (CT)/positron emission tomography (PET) imaging to monitor stable disease or tumor progression. More recently, the implementation of a noninvasive “liquid biopsy” has been destined to capture tumor-specific genetic clonal evolution throughout the course of cancer therapy. This case report focuses on circulating cell-free tumor DNA (ctDNA) in the bloodstream as a versatile biomarker, enabling accurate monitoring of tumor burden and treatment response. Our observations showed that [1] mutation load measured by blood-drop ctDNA sequencing correlated well with PE...

Juniper Publishers-Open Access Journal of Cancer Therapy and Oncology New Cancer Therapies Authored by Daniela Vazquez Capdepon Malignant neoplasms are the second cause of death in Argentina, according to official data from the Argentine Ministry of Health, 25% of annual deaths are due to cancer, although it has detected a reduction of approximately 10% mortality rate cancer over the last 15 years. This condition causes between 55 and 60,000 deaths annually in Argentina. Values between 1% and 2.5% of the adult population, with a strong increase as the population ages. The new systemic cancer therapies are the result of decades of investment in research and clinical.  The two-way interaction between the clinic and the lab opened a whole new outlook, with a growing universe of “new molecular targets” possible to be manipulated pharmacologically. The mechanisms of regulation of cell signaling, generation of neovasculature (angiogenesis), cell cycle control...

Juniper Publishers-Open Access Journal of Cancer Therapy and Oncology Chemoradiation with Capecitabine and Mitomycin-C for Stage I-III Anal Squamous Cell Carcinoma Authored by Hagen Kennecke Carcinoma of the anal canal is relatively uncommon, yet incidence is on the rise. The accepted current standard regimen for patients with stage I-III squamous cell carcinoma (SCC) of the anal canal is radiotherapy (50.4 Gy) with concurrent infusional 5-fluorouracil (5-FU) (825 mg/m2 per oral bi-daily) administered on radiation days during weeks one and five and mytomycin C (MMC) (12 mg/m2) administered on week one. This study describes the efficacy and safety of substituting oral capecitabine (Cap) for the infusional 5-FU and compares the planned versus delivered therapy, and describes treatment-related patient toxicities and early outcomes in a population-based setting. To Read More. . PHP  in  Cancer Therapy & Oncology International Journal  in Junip...

Juniper Publishers-Open Access Journal of Cancer Therapy and Oncology How Long Should Be The Radiation Oncology Treatment for Cervical Cancer? Authored by Luis Moreno Sanchez Historically locally advanced cervical cancer was treated with teletherapy and a boost with brachytherapy. But in 1999 the treatment changed favorably, thus establishing the current management based on concurrent chemo-radiotherapy, thanks to the publication of some studies [1,2] that showed survival advantage of this disease with the addition of platinum-based chemotherapy and radiotherapy. To Read More.. PHP  in Cancer Therapy & Oncology International Journal  in Juniper Publishers

Juniper Publishers-Open Access Journal of Cancer Therapy and Oncology Can Dynamic Conformal arc be an Option in Epidermoid Cervical Cancer Treatment? Authored by  Jacksson S Historically locally advanced cancer of the cervix has been treated with radiotherapy and brachytherapy and it was not until 1999 that the use of concurrent chemotherapy was formalized due to excellent results in terms of rate of overall and disease-free survival. Box technique in radiotherapy is the most widely known providing excellent results, with some variations as oblique fields, but greatly increasing irradiation potentially healthy tissue, leading to the higher proportion of own side effects of each treatment. Therefore present a radiant treatment planning mode Dynamic Conformal Arc for cervical carcinoma.Treatment with dynamic conformal arc achieves better conformation of tumor and area to be treated, avoiding unnecessary doses to organs at risk (OAR), compared to conventional ...

Juniper Publishers-Open Access Journal of Cancer Therapy and Oncology BRCA1 and BRCA2 Mutations are they Related to Breast Cancer in a Sample of Tunisian Population? Authored by Awatef Msolly Mutations in the BRCA1/BRCA2 genes account for varying proportions of breast cancer families studied, and demonstrate considerable variation in mutational spectra coincident with ethnic and geographical diversity. This work aimed to identify mutations in BRCA1 and BRCA2 genes to explore the existence of population-specific recurrent or founder mutations, in Tunisian breast cancer families. We have screened for germline mutations in seventeen Tunisian high-risk breast cancer patients using direct sequencing. Index patients, diagnosed before age 45, possessing a positive family history or bilateral breast cancer were asked for detailed information on family history of breast or any other cancer type in their families. One family out of 17 (6%) carried BRCA 1 mutations and ...